Journal of Cardiovascular Pharmacology · 2011 · 33 citations · 25 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyInflammationMolecular PharmacologyAtherosclerosis PharmacotherapyCardiac MedicationsCardiovascular DiseaseCardiovascular PharmacodynamicsCardiovascular PharmacologyHypertension PharmacotherapyAngiotensin Ii Receptor BlockersAortic Wall BiologyAtherosclerosis Molecular MechanismsAtherosclerotic ProgressionAtherosclerotic Risk ReductionPlaque StabilizationPlasminogen ActivatorsVascular Smooth Muscle Pharmacology
Increased expression of plasminogen activator inhibitor type-I (PAI-1) in vessel walls seems to accelerate atherosclerosis. Angiotensin II can increase the synthesis of PAI-1. Inhibition of this process may facilitate migration of vascular smooth muscle cells (VSMCs) stabilizing atherosclerotic plaques. To determine whether the inhibition of the angiotensin II type 1 receptor can blunt the expression of PAI-1 protein in the aortic wall, we administered azilsartan medoxomil (AZL-M), a prodrug of an angiotensin II type 1 receptor blocker developed by the Takeda Pharmaceutical Company Limited, for 16 weeks to ApoE knockout mice on a high fat diet rendered overexpressors of PAI-1 in VSMCs. Homogenates of the pooled aortas from each group were assayed for PAI-1 by enzyme-linked immunosorbent assay. Cellularity of atherosclerotic lesions was assessed by 4',6-diamidino-2-phenylindole staining in sections of aortic lesions, and collagen content in the lesions was quantified by immunohistochemistry. Aortic wall PAI-1 was decreased by each of the 3 dosage regimens of AZL-M (0.1-10 mg/kg). Cellularity and collagen were increased in lesions from mice given AZL-M, consistent with the development of more stable plaques. Accordingly, the suppression of PAI-1 expression by AZL-M may attenuate the evolution of atherosclerotic plaques vulnerable to rupture.
25
Heart Disease and Stroke Statistics—2010 Update
Donald M. Lloyd‐Jones, Robert J. Adams, Todd M. Brown et al. · Circulation · 2009 · 5.6K citations
PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION
Anders Hamsten, Göran Walldius, Alfred Szamosi et al. · The Lancet · 1987 · 1.5K citations
Erling Falk · Circulation · 1985 · 1.1K citations